2N Pharma Holding ApS: Financial statements 2023
CVR: 42523453
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
2N Pharma Holding ApS (CVR 42523453) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK -31,303 and a net result of DKK -948,734. Equity in the 2023 report amounted to DKK -1,132,310.
- Gross Profit
- DKK -31,303
- Profit/Loss
- DKK -948,734
- Equity
- DKK -1,132,310
- Total Assets
- DKK 11,284,836
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
As of September 4, 2023, John Kemp has left the board of directors of 2N Pharma Holding ApS.
As of August 31, 2023, Alex Leech has left the board of directors of 2N Pharma Holding ApS.
2N Pharma Holding ApS has published its interim report for the period July 6, 2021 – December 31, 2022.
About 2N Pharma Holding ApS
2N Pharma Holding ApS is a Danish company of the type Anpartsselskab based in Aalborg Øst, founded in 2021. The company is under bankruptcy. The company is registered under the industry Ikke-finansielle holdingselskaber. The company is owned by Neurometa Therapeutics AB. In 2024, the company reported a gross profit of DKK -38,812 and a net result of DKK -1,033,166 compared with DKK -948,734 the year before. Equity in the 2024 report amounted to DKK -2,165,476.